Cargando…
Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis
We aimed to provide insights on the role of the circadian time of administration in influencing the efficacy and tolerability/safety profile of OnabotulinumtoxinA (BoNTA) for chronic migraine (CM) prophylaxis. Methods: We retrospectively reviewed the medical files of BoNTA-naïve patients with CM who...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145697/ https://www.ncbi.nlm.nih.gov/pubmed/35622543 http://dx.doi.org/10.3390/toxins14050296 |
_version_ | 1784716378868023296 |
---|---|
author | Dermitzakis, Emmanouil V. Vikelis, Michail Vlachos, George S. Argyriou, Andreas A. |
author_facet | Dermitzakis, Emmanouil V. Vikelis, Michail Vlachos, George S. Argyriou, Andreas A. |
author_sort | Dermitzakis, Emmanouil V. |
collection | PubMed |
description | We aimed to provide insights on the role of the circadian time of administration in influencing the efficacy and tolerability/safety profile of OnabotulinumtoxinA (BoNTA) for chronic migraine (CM) prophylaxis. Methods: We retrospectively reviewed the medical files of BoNTA-naïve patients with CM who completed three consecutive cycles of treatment, according to the standard PREEMPT paradigm. Participants were classified to those scheduled to be treated in the morning hours from 8:00 to 12:00 (AM) or afternoon hours from 13:00 to 18:00 (PM). We then assessed and compared between groups the changes from baseline (T0—trimester before BoNTA’s first administration) to the period after its third administration (T3) in the following efficacy outcomes: (i) mean number of headache days/month, (ii) mean number of days/month with peak headache intensity of >4/10, (iii) mean number of days/month with consumption of any abortive treatment. Safety–tolerability was also compared between groups. Results: A total of 50 AM and 50 PM-treated patients were evaluated. The within-group analysis in both groups showed a significant decrease in all efficacy variables between T0 and T3. However, the between-group comparisons of all BoNTA-related efficacy outcomes at T3 vs. T0 documented comparable improvements between AM vs. PM-treated patients. Safety/tolerability was also similar between groups. Conclusions: We were not able to identify significant differences between patients treated in the AM vs. PM, so as to demonstrate that the circadian time of administration should be considered before initiating BoNTA in CM patients. |
format | Online Article Text |
id | pubmed-9145697 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91456972022-05-29 Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis Dermitzakis, Emmanouil V. Vikelis, Michail Vlachos, George S. Argyriou, Andreas A. Toxins (Basel) Article We aimed to provide insights on the role of the circadian time of administration in influencing the efficacy and tolerability/safety profile of OnabotulinumtoxinA (BoNTA) for chronic migraine (CM) prophylaxis. Methods: We retrospectively reviewed the medical files of BoNTA-naïve patients with CM who completed three consecutive cycles of treatment, according to the standard PREEMPT paradigm. Participants were classified to those scheduled to be treated in the morning hours from 8:00 to 12:00 (AM) or afternoon hours from 13:00 to 18:00 (PM). We then assessed and compared between groups the changes from baseline (T0—trimester before BoNTA’s first administration) to the period after its third administration (T3) in the following efficacy outcomes: (i) mean number of headache days/month, (ii) mean number of days/month with peak headache intensity of >4/10, (iii) mean number of days/month with consumption of any abortive treatment. Safety–tolerability was also compared between groups. Results: A total of 50 AM and 50 PM-treated patients were evaluated. The within-group analysis in both groups showed a significant decrease in all efficacy variables between T0 and T3. However, the between-group comparisons of all BoNTA-related efficacy outcomes at T3 vs. T0 documented comparable improvements between AM vs. PM-treated patients. Safety/tolerability was also similar between groups. Conclusions: We were not able to identify significant differences between patients treated in the AM vs. PM, so as to demonstrate that the circadian time of administration should be considered before initiating BoNTA in CM patients. MDPI 2022-04-21 /pmc/articles/PMC9145697/ /pubmed/35622543 http://dx.doi.org/10.3390/toxins14050296 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Dermitzakis, Emmanouil V. Vikelis, Michail Vlachos, George S. Argyriou, Andreas A. Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis |
title | Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis |
title_full | Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis |
title_fullStr | Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis |
title_full_unstemmed | Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis |
title_short | Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis |
title_sort | assessing the significance of the circadian time of administration on the effectiveness and tolerability of onabotulinumtoxina for chronic migraine prophylaxis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145697/ https://www.ncbi.nlm.nih.gov/pubmed/35622543 http://dx.doi.org/10.3390/toxins14050296 |
work_keys_str_mv | AT dermitzakisemmanouilv assessingthesignificanceofthecircadiantimeofadministrationontheeffectivenessandtolerabilityofonabotulinumtoxinaforchronicmigraineprophylaxis AT vikelismichail assessingthesignificanceofthecircadiantimeofadministrationontheeffectivenessandtolerabilityofonabotulinumtoxinaforchronicmigraineprophylaxis AT vlachosgeorges assessingthesignificanceofthecircadiantimeofadministrationontheeffectivenessandtolerabilityofonabotulinumtoxinaforchronicmigraineprophylaxis AT argyriouandreasa assessingthesignificanceofthecircadiantimeofadministrationontheeffectivenessandtolerabilityofonabotulinumtoxinaforchronicmigraineprophylaxis |